Fund Details
Nippon India Pharma Fund Dividend
| Risk | High |
|---|---|
| Min SIP Amount | ₹100 |
| Expense Ratio | 2.02% |
| NAV | ₹80.70 (20 Jan 2021) |
|---|---|
| Fund Started | 05 Jun 2004 |
| Fund Size | ₹4,383 Cr |
Returns
Comparison
1. Age is more than 10 years
2. Risk is lower compared to the benchmark
3. 1Y Returns are higher than the benchmark
4. 3Y Returns are higher than the benchmark
5. 5Y Returns are higher than the benchmark
6. Age is more than 10 years
7. 3Y Returns are higher than the category average returns
8. 5Y Returns are higher than the category average returns
9. 10Y Returns are higher than the category average returns
1. Risk-adjusted returns are lower compared to the category
2. Higher expense ratio
3. 10Y Returns are lower than the benchmark
4. Risk-adjusted returns are lower compared to the category
5. Higher expense ratio - 2.19%
6. 1Y Returns are lower than the category average returns
Top Holdings
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Aurobindo Pharma Ltd. | Healthcare | Equity | 10.5% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.9% |
| Divi's Laboratories Ltd. | Healthcare | Equity | 9.6% |
| Cipla Ltd. | Healthcare | Equity | 9.0% |
| Lupin Ltd. | Healthcare | Equity | 8.6% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Equity | 7.3% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 6.5% |
| Gland Pharma Ltd. | Healthcare | Equity | 6.5% |
| Thyrocare Technologies Ltd. | Healthcare | Equity | 5.6% |
| Fortis Healthcare (India) Ltd | Healthcare | Equity | 5.2% |
Fund Managers
Nippon India Pharma Fund Dividend Details
Nippon India Pharma Fund Dividend is a Equity Mutual Fund Scheme launched by Nippon India Mutual Fund. This scheme was made available to investors on 05 Jun 2004. Sailesh Raj Bhan is the Current Fund Manager of Nippon India Pharma Fund Dividend fund.The fund currently has an Asset Under Management(AUM) of ₹4,383 Cr and the Latest NAV as of 20 Jan 2021 is ₹80.70.
The Nippon India Pharma Fund Dividend is rated High risk. Minimum SIP Investment is set to 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 1 month.
Investment Objective
The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.
Tax Implications
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.
